Table 1 Clinicopathological characteristics, MYC , hTERT and TP53 expression , and TP53 copies in gastric samples
From: hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions
Superficial gastritis | Atrophic gastritis | Intestinal metaplasia | |
|---|---|---|---|
Gender | |||
Male [N (%)] | 12 (63.2) | 11 (61.1) | 12 (66.7) |
Female [N (%)] | 7(36.8) | 7 (38.9) | 6 (33.3) |
Alcohol consumption | |||
Negative [N (%)] | 10 (52.6) | 10 (55.6) | 12 (66.7) |
Positive [N (%)] | 9 (47.4) | 8 (44.4) | 6 (33.3) |
Cigarette smoking | |||
Negative [N (%)] | 10 (52.6) | 12 (66.7) | 9 (50) |
Positive* [N (%)] | 9 (47.4) | 6 (33.3) | 9 (50) |
H. pylori infection | |||
Negative [N (%)] | 7 (36.8) | 5 (27.8) | 1 (5.6) |
Positive [N (%)] | 12 (63.2) | 13 (72.2) | 17 (94.4) |
hTERT mRNA expression | |||
RQ (Mean ± SD) | 1.092 ± 0.61 | 0.821 ± 0.47 | 1.184 ± 0.55 |
MYC mRNA expression | |||
RQ (Mean ± SD) | 0.852 ± 0.51** | 0.873 ± 0.28** | 1.901 ± 0.49 |
TP53 mRNA expression | |||
RQ (Mean ± SD) | 0.997 ± 0.59 | 0.847 ± 0.79 | 1.021 ± 0.61 |
hTERT immunoreactivity | |||
Negative [N (%)] | 19 (100) | 18 (100) | 10 (55.6) |
Positive [N (%)] | 0 (0)** | 0 (0)** | 8 (44.4) |
MYC immunoreactivity | |||
Negative [N (%)] | 19 (100) | 18 (100) | 10 (55.6) |
Positive [N (%)] | 0 (0)** | 0 (0)** | 8 (44.4) |
p53immunoreactivity | |||
Negative [N (%)] | 19 (100) | 18 (100) | 12 (66.7) |
Positive [N (%)] | 0 (0)** | 0 (0)** | 6 (33.3) |
TP53 copies | |||
2 copies [N (%)] | 18 (100) | 18 (100) | 15 (83.3) |
1 copy [N (%)] | 0 (0) | 0 (0) | 3 (16.7)*** |